Literature DB >> 17854729

Integrating HCV services for drug users: a model to improve engagement and outcomes.

Diana L Sylvestre1, Joan E Zweben.   

Abstract

Although the majority of prevalent and incident cases of hepatitis C are related to injection drug use, drug users often find it difficult to access treatment services because of concerns about adherence and treatment candidacy. In response to the growing epidemic, OASIS, a nonprofit community clinic, developed a successful peer-based HCV group that allowed us to engage, educate, test, and treat hepatitis C in large numbers of drug users, the majority of whom have multiple potential barriers to intervention. Integrating services for hepatitis C, addiction, mental health, and psychosocial problems, the model involves a collaboration of medical providers and peer educators and incorporates elements of other proven behavioural models, including self-help groups, therapeutic communities, and peer interventions. Our results indicate that this peer-based model is successful at engaging, educating, and treating a diverse spectrum of chaotic drug users. We conclude that an integrated, peer-based approach to intervention can engage even the most challenging addicted patients with hepatitis C, and can facilitate their successful screening and treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17854729     DOI: 10.1016/j.drugpo.2007.01.010

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  37 in total

1.  Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.

Authors:  R Douglas Bruce; Julie Eiserman; Angela Acosta; Ceilia Gote; Joseph K Lim; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2012-01-13       Impact factor: 3.829

2.  Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs.

Authors:  Megan G Hofmeister; Jennifer R Havens; April M Young
Journal:  J Prim Prev       Date:  2017-10

3.  Strategies used by people who inject drugs to avoid stigma in healthcare settings.

Authors:  Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi
Journal:  Drug Alcohol Depend       Date:  2019-03-08       Impact factor: 4.492

Review 4.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

5.  Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?

Authors:  Lynn E Taylor; Michaela A Maynard; Peter D Friedmann; Cynthia J Macleod; Josiah D Rich; Timothy P Flanigan; Diana L Sylvestre
Journal:  J Addict Med       Date:  2012-09       Impact factor: 3.702

6.  Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.

Authors:  Jennifer M Loftis; Alexander L Patterson; Clare J Wilhelm; Henry McNett; Benjamin J Morasco; Marilyn Huckans; Timothy Morgan; Shira Saperstein; Aliya Asghar; Peter Hauser
Journal:  J Psychosom Res       Date:  2012-11-21       Impact factor: 3.006

7.  Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.

Authors:  Lynn E Taylor; Sarah E Bowman; Stacey Chapman; Nickolas Zaller; Michael D Stein; Patricia A Cioe; Michaela A Maynard; Barbara Hedgis McGovern
Journal:  Drug Alcohol Depend       Date:  2010-12-21       Impact factor: 4.492

8.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

9.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

10.  Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.

Authors:  Adam Isaiah Newman; Shelley Beckstead; David Beking; Susan Finch; Tina Knorr; Carol Lynch; Meredith MacKenzie; Daphne Mayer; Brenda Melles; Ron Shore
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.